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ARTICLE OPEN
Interrogation of a live-attenuated enterotoxigenic Escherichia
coli vaccine highlights features unique to wild-type infection
Subhra Chakraborty1, Arlo Randall2, Tim J. Vickers3, Doug Molina2, Clayton D. Harro1, Barbara DeNearing1, Jessica Brubaker1,
David A. Sack1, A. Louis Bourgeois1, Philip L. Felgner2,4, Xiaowu Liang2, Sachin Mani 5, Heather Wenzel5, R. Reid Townsend6,
Petra E. Gilmore6, Michael J. Darsley7, David A. Rasko8 and James M. Fleckenstein 3,9
Enterotoxigenic Escherichia coli (ETEC) infections are a common cause of severe diarrheal illness in low- and middle-income
countries. The live-attenuated ACE527 ETEC vaccine, adjuvanted with double mutant heat-labile toxin (dmLT), affords clear but
partial protection against ETEC challenge in human volunteers. Comparatively, initial wild-type ETEC challenge completely protects
against severe diarrhea on homologous re-challenge. To investigate determinants of protection, vaccine antigen content was
compared to wild-type ETEC, and proteome microarrays were used to assess immune responses following vaccination and ETEC
challenge. Although molecular interrogation of the vaccine conﬁrmed expression of targeted canonical antigens, relative to wild-
type ETEC, vaccine strains were deﬁcient in production of ﬂagellar antigens, immotile, and lacked production of the EtpA adhesin.
Similarly, vaccination ± dmLT elicited responses to targeted canonical antigens, but relative to wild-type challenge, vaccine
responses to some potentially protective non-canonical antigens including EtpA and the YghJ metalloprotease were diminished or
absent. These studies highlight important differences in vaccine and wild-type ETEC antigen content and call attention to distinct
immunologic signatures that could inform investigation of correlates of protection, and guide vaccine antigen selection for these
pathogens of global importance.
npj Vaccines            (2019) 4:37 ; https://doi.org/10.1038/s41541-019-0131-7
INTRODUCTION
Enterotoxigenic Escherichia coli (ETEC) cause substantial morbidity
due to diarrheal illness in resource-poor areas of the world where
young children are disproportionately affected. In children under
ﬁve years of age, these pathogens are among the leading causes
of moderate-to-severe diarrhea and deaths due to acute diarrheal
illness.1,2 ETEC also causes severe illness, clinically indistinguish-
able from cholera,3–5 and death in older individuals6 and remains
the most common cause of travelers’ diarrhea. While oral
rehydration therapy and other measures have contributed to a
decline in deaths due to diarrheal illness, ETEC have been linked to
post-diarrheal sequelae including malnutrition, growth stunting,
and impaired cognitive development greatly compounding the
impact of these infections.7
The ETEC pathovar is deﬁned by the production and effective
delivery of heat-stable (ST) and/or heat-labile (LT) enterotoxins to
epithelial receptors in the small intestine. In the classical ETEC
pathogenesis paradigm, plasmid-encoded colonization factor (CF)
or coli surface (CS) antigens facilitate small intestinal colonization.8
Interaction with small intestinal enterocytes leads to toxin-induced
alterations in salt and water transport that result in net ﬂuid losses
into the intestinal lumen and ensuing watery diarrheal illness
ranging from mild to severe and cholera-like.3
ETEC infections among young children in endemic regions are
thought to result in acquired immunity and a decreasing
incidence of infection with age.9 Indeed, controlled human
infection studies demonstrate that homologous re-challenge with
the ETEC H10407 strain, which encodes CFA/I, results in robust
protection against symptomatic ETEC infection.10 However,
precise correlates of protection11 have not been established,
and the majority of immunologic studies have focused on
canonical virulence factors, namely the CF/CS antigens and heat-
labile toxin. Nevertheless, recent studies indicate that the
repertoire of immune responses following infection extends
beyond these classical antigens.12
Because of inherent genetic plasticity of E. coli, no canonical
virulence factor is universally conserved in ETEC. Therefore, to
achieve broad coverage, most ETEC vaccines under development
adopt a polyvalent approach targeting multiple CF/CS antigens
and LT. ACE527, was developed as a live-attenuated vaccine
combining three strains that collectively express CS1, CS2, CS3,
CS5, CS6, CFA/I, and the B subunit of LT.13
In recent studies vaccination with ACE527 alone failed to
protect against severe diarrhea upon challenge with H10407,
while ACE527 adjuvanted with double mutant heat-labile toxin
(dmLT)14 afforded signiﬁcant protection (PE ~ 66%) (Clinical Trials
Identiﬁer NCT01739231).15 Comparatively, H10407 challenge
elicits nearly complete protection against homologous re-
challenge.10 To comprehensively assess the adaptive immune
response to vaccination we examined the antigen continent of
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ACE527 and used ETEC protein microarrays to examine antibody
responses to the vaccine ± dmLT. These responses were then
compared to vaccine placebo controls and to challenge with
H10407 to proﬁle potential benchmarks of protection.
RESULTS
Genomic and proteomic characterization of ACE527 vaccine
strains
Whole genome DNA sequence data was used to verify the
genotypes of wild-type parental isolates and the engineering of
the ACE527 strains (summarized in supplementary table 1). As
anticipated,13 the three engineered vaccine strains, ACAM2022,
ACAM2025, and ACAM2027, collectively encoded the full comple-
ment of six CF/CS antigens (CFA/I, CS1,CS2, CS3, CS5, and CS6),
and each encoded both the B subunit of heat-labile toxin, as well
as the type II secretion system (T2SS) responsible for export of
both LT16 and YghJ17 (supplementary table 3). Two of the three
parental strains, WS1858B and WS3504D were noted to contain
the plasmid etpBAC locus which encodes the two-partner
secretion system responsible for production and export of the
EtpA adhesin,18 however analysis of the corresponding attenuated
vaccine derivatives, ACAM2025 and ACAM2027 revealed that this
locus had been lost in the vaccine strain construction (Fig. 1a, b).
Similarly, the eatA gene which encodes a serine protease
autotransporter protein that degrades MUC2 mucin,19 was present
in each of the parents but absent from ACAM2025 (Fig. 1a, b).
The growth of each parental isolate and corresponding ACAM
live-attenuated bacteria was compared to H10407. In general, the
growth of the parental wild-type strains paralleled that of H10407,
Fig. 1 vaccine strain molecular characterization. a PCR conﬁrmation of ACE527 genotypes. Shown are (top) multiplex enterotoxin (eltB, estP,
and estH) PCR; (middle) eatA autotransporter gene; (bottom) etpA ampliﬁcation from wild-type parental ETEC strains, corresponding live-
attenuated ACE527 vaccine constructs, and controls. H10407 and MG1655 are shown at right as a positive and negative controls, respectively.
b Immunoblots (TCA-precipitated culture supernatants) for secreted antigens EatA passenger domain (EatAp), the EtpA adhesin, and the YghJ
metalloprotease. (Gel and blot images in (a) and (b) respectively were each derived from a single set of experiments). c Growth curves of
parental strains (closed symbols) and corresponding vaccine strains (open symbols). H10407 growth curve (blue symbols) is shown for
comparison. Summary of proteomic data from interrogation of ACE527 parents and vaccine strains. Parent strain and corresponding mutant
are paired on the X axis. d Heat map values reﬂect the maximum normalized total spectra obtained from analysis of secretome, outer
membrane and outer membrane vesicles. Colonization factors are grouped at the top of the map and color-coded on the Y axis by function.
e ACE527 parental and vaccine strains are immotile in soft agar assays. H10407 (bottom left) and an isogenic ﬂiC mutant (bottom right) are
shown as positive and negative motility controls, respectively
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while the growth of ACAM vaccine strains lagged slightly,
potentially reﬂecting the combined effect of OmpC and OmpF
mutations on growth20 (Fig. 1c).
In keeping with the analysis of the individual genomes, mass
spectrometry studies veriﬁed production of one or more features
of the anticipated CF antigens, including outer membrane usher
proteins, and major and minor pilin subunits, as well as LT-B in
each of the vaccine strains. As anticipated, no EatA protein was
detected in the supernatant of ACAM2025 and no EtpA was
produced by the vaccine strains (Fig. 1d, supplementary dataset
2). Interestingly, we noted substantially increased expression of
several iron-siderophore transport proteins including FepA, CirA,
and Fiu in vaccine strains relative to the corresponding parents,
possibly due to the absence of OmpC, and OmpF porins, and the
complex regulation of the outer membrane architecture by small
non-coding rRNAs known to govern the production of CirA and
FepA.21
In contrast to recent studies of the H10407 proteome12 where
the major protein subunit of ﬂagella, ﬂagellin (FliC, serotype H11),
and the ﬂagellar hook protein, FlgE were present in abundance,
FliC was not universally detected in the ACE527 proteomes, and
we were unable to detect the ﬂagellar hook protein, FlgE (Fig. 1d).
Despite the identiﬁcation of the ﬂagellar operons in the genomes
of all of the parent and mutant strains, we found that none of the
ACE527 or progenitor strains were motile (Fig. 1e).
Collectively, these molecular characterization studies demon-
strated that the ACE527 vaccine strains express all of the canonical
ETEC antigens targeted in construction of the vaccine. However,
they lack some virulence properties previously identiﬁed in the
H10407 challenge strain including motility, production of key
ﬂagellar antigens, and other immunogenic proteins including the
secreted EtpA blood group A lectin-adhesin.12,22
Differential immune responses to ETEC antigens after vaccination
and challenge
Recent controlled human infection studies with the H10407 strain
of ETEC demonstrated that previously naive volunteers mount
strong mucosal antibody responses to classical vaccine targets
including CFA/I and heat-labile toxin as well as a select number of
molecules that have not been traditionally been targeted in
vaccines.12 Here we set out to examine immune response to the
classical antigens targeted in ACE527, and to a broadly inclusive
ETEC proteome represented on microarrays incorporating more
than 4000 proteins.
Mucosal antibody, particularly mucosal IgA, is felt to be an
essential determinant of protection against ETEC, that follows
natural infection. Antibody secreted by circulating gut-homing
lymphocytes can be obtained from peripheral blood mononuclear
cells (PBMC) following recent mucosal exposure to antigens from
enteric pathogens.23,24 These antibody lymphocyte supernatants
(ALS) serve as a convenient hallmark of recent mucosal antigen
exposure. Therefore, we tested ALS samples from individuals who
received ACE527 ± dmLT and placebo controls prior to vaccina-
tion, after vaccination, and following challenge with ETEC H10407.
Response to classical vaccine antigens
Following vaccination with either ACE527 or ACE527 adjuvanted
with dmLT, we observed increases in ALS IgA immunoreactivity to
most canonical antigens targeted in the vaccine. Seven days after
vaccination, we found that each subject mounted robust
responses to CFA/I, and the majority (≥75%) responded to B
subunit of LT (Fig. 2, Table 1). In addition, we found strong
responses in both groups to PCF071, with subjects responding this
class 5b ﬁmbrial antigen most closely related to CS125 Table 1,
supplementary ﬁg. 1, while we observed more modest responses
to CS17 another class 5b antigen, or CooD, a minor pilin subunit of
CS1.26 More than half of vaccine recipients also mounted ALS IgA
responses to CS2 and/or the CotA CS2 pilin in each of the vaccine
groups. Responses to CS3 were strongest in the dmLT adjuvanted
cohort where nearly 2/3 of recipients demonstrated increased
responses following vaccination (Table 1). Altogether, these data
demonstrate that vaccination with ACE527 with or without dmLT
results in antibody responses to most classical antigens targeted
in the vaccine. CS6 was an exception in this regard. Interestingly,
an earlier analysis of samples from individuals immunized with
ACE527, prepared from frozen lots of the vaccine, demonstrated a
13-fold increase in peak geometric mean ALS titers from
baseline.27 Whether drying of the lyophilized preparation of the
vaccine used in the present studies impacted the stability or
presentation of the CS6 antigens to the recipients in the present
study is presently unclear.
Response to non-canonical antigens following vaccination and
challenge
Although ACE527 was directed at classical ETEC CF/CS and LT-B
vaccine antigens, recent studies indicate that following ETEC
infection, subjects respond to antigens not targeted in canonical
vaccine strategies. Following earlier H10407 challenge studies,
we found that all subjects mounted robust responses to ﬂagellin
(FliC), the major protein subunit of ﬂagella .12 Interestingly,
however, consistent with poor production of ﬂagellin and the
lack of motility by the ACE527 vaccine strains, we found that
fewer than 1/3 of the recipients of unadjuvanted ACE527
developed signiﬁcant responses to FliC regardless of serotype.
Notably, we found that following administration of the vaccine+
dmLT the majority (92%) of recipients mounted responses to at
least one ﬂagellin molecule. Interestingly, these enhanced
responses were not constrained to serotypes included in the
vaccine as 10/13 subjects in the dmLT cohort responded to FliC
from serotype H11 (Fig. 3a, Table 2) the serotype for H10407
challenge strain. As this serotype was not included in the vaccine
itself, and responses to H-serotype speciﬁc regions of the ﬂagellins
represented in the vaccine were noticeably absent (supplemen-
tary ﬁg. 2), the responses to FliC H11 and other ﬂagellins may
reﬂect recognition of the non-serotype speciﬁc highly conserved
alpha helical regions comprising the amino and carboxy terminal
regions of ﬂagellin molecules (supplementary ﬁg. 3).
We likewise observed differential responses to two secreted
non-canonical antigens, the passenger domain of the EatA
autotransporter protein, and YghJ a metalloprotease secreted by
the type 2 secretion system. Both proteins were recognized
following vaccination with ACE527 with 9/12 subjects responding
to the EatAp and 6/12 responding to YghJ. These responses were
enhanced slightly in the dmLT cohort (Table 1).
Immune responses to non-canonical proteins predominate after
challenge
In naive subjects and in vaccine recipients challenged with
H10407, we noted enhanced responses to a number of proteins
that were not recognized following vaccination. Among the most
striking differential responses following challenge compared to
vaccination were those to ﬂagellar proteins. 9/10 placebo
vaccinated subjects responded to both full length and the
serotype speciﬁc region (AA174-399) of FliC H11 (Table 3).
Likewise, 6/10 volunteers responded to the FlgE ﬂagellar hook
protein, a response that was absent in vaccinees prior to
challenge, consistent with the lack of motility in the
ACE527 strains and the absence of FlgE in the ACE527 proteomes.
In addition to ﬂagellin, three secreted antigens YghJ (SslE),28
EatA,19 and EtpA,29 not currently targeted in classical ETEC vaccine
approaches have been shown to be immunogenic in humans12
and associated with protection in animal models.19,29–31 Although
we observed responses to YghJ following vaccination with either
ACE527 or ACE527+ dmLT, the response to this protein was
S. Chakraborty et al.
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signiﬁcantly increased following challenge with H10407 (Fig. 3b).
Similarly, we observed the most robust responses to the EatA
passenger domain following challenge with H10407 (Fig. 3c). In
contrast, in keeping with the absence of EtpA in the three vaccine
strains, vaccinees did not recognize EtpA following immunization,
while both the placebo group and the vaccinated subjects
mounted robust responses to EtpA upon challenge with H10407
(Fig. 3d, Table 4).
Fig. 2 Immune response to puriﬁed colonization factor antigens and secreted ETEC virulence factors following vaccination and challenge.
Bar graphs on left depict the difference in mean ALS IgA responses from day-1 to day 7 following vaccination with placebo, ACE527, and
ACE527+ dmLT (gray bars), or following challenge with H10407 (blue bars). Antigens listed on the Y axis include all major colonization
factors and subunits (top) and secreted virulence proteins LT (A and B subunits), EtpA (carboxy terminal repeat region EtpAc, and amino
terminal secretion domain Etpn), EatA (passenger domain EatAp), and YghJ (bottom). The column on the far left indicates antigens present
in (+) or absent from (−) the ACE527 vaccine strains. Antigens present in the H10407 challenge strain are depicted in Blue. Heat map at
right depicts the proportion of volunteers exhibiting at least a 50% increase in signal intensity at day 7 following vaccination relative to
baseline (day 0) values. Challenge values depicted are from day 7 following challenge of the placebo group with H10407
Table 1. Most differentially reactive puriﬁed protein antigens ALS IgA, responses day 0 to day 7 following ACE527 or ACE527+ dmLT
ACE527 ACE527+ dmLT
Antigen Δa Frequencyb p antigen Δa Frequencyb p
CFA/I 4.34 1.00 5.4 × 10–6 CFA/I 4.81 1.00 8.4 × 10–7
PCF071 3.66 1.00 4.1 × 10–6 PCF071 3.08 1.00 5.2 × 10–7
LT-B 2.04 0.75 3.2 × 10–3 EatAp 2.74 0.85 1.6 × 10–4
EatAp 1.62 0.75 7.8 × 10–3 LT-B 2.90 0.77 7.7 × 10–4
CS2 1.41 0.58 1.5 × 10–2 CS3c 1.09 0.62 2.0 × 10–2
YghJ 0.93 0.50 1.2 × 10–2 YghJ 0.80 0.62 3.0 × 10–2
CS17 0.82 0.50 3.4 × 10–2 CS2 1.14 0.54 1.7 × 10–2
CotA (CS2 pilin) 0.70 0.42 2.8 × 10–2 CooD 1.15 0.46 1.3 × 10–2
CsuD (CS14 adhesin) 0.39 0.42 2.1 × 10–2 CS17 1.04 0.38 3.9 × 10–2
CstH (CS3 pilin) 1.04 0.33 7.0 × 10–2 CfaB 1.34 0.31 3.0 × 10–2
aΔmean refers to difference in mean values at day 0 and day 7 with respect to the ﬁrst vaccination
bFrequency refers to the proportion of subjects with at least a 50% increase in normalized signal intensity between day 0 and day 7 after the ﬁrst vaccination
cPuriﬁed ﬁmbriae
S. Chakraborty et al.
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DISCUSSION
A systematic appraisal of immune response to candidate vaccines
can aid in vaccine optimization and identiﬁcation of mechanistic
correlates of protection. Here, we combined genomic and
proteomic interrogation of a live-attenuated vaccine with
immunoproteomic analysis following vaccination and experimen-
tal human challenge with ETEC H10407, an extensively character-
ized strain originally obtained from a patient with severe cholera-
like diarrheal illness.32 Previous studies demonstrating that
challenge with wild-type ETEC H10407 bacteria affords virtually
complete protection against severe diarrhea on subsequent re-
challenge10 provide important benchmarks for comparison of
candidate vaccines. Importantly, the studies reported here high-
light a number of features that distinguish the vaccine strains from
the challenge strain and the corresponding immune responses.
First, although the wild-type isolates used to construct the
vaccine had previously been serotyped for ﬂagellar (H) antigens,
we found that production of ﬂagellin, the major subunit of ﬂagella,
by both the parent and the vaccine strains was deﬁcient, and none
were motile upon testing. Similarly, contrasting with our earlier
analysis of the H10407 challenge strain,12 we were unable to
detect FlgE, the ﬂagellar hook protein, in either the parental or
vaccine strains, suggesting that despite the presence of the genes
required for assembly, early steps involved in biosynthesis of
ﬂagella are deﬁcient33,34 in the isolates selected for engineering of
ACE527. These deﬁciencies may have negatively impacted the
protection afforded by the vaccine in a number of ways including
loss of TLR5 mediated stimulation of innate immunity, and the
potent adjuvant activity of ﬂagellin. While H serotypes of ETEC
vary considerably,35 motility is a highly conserved virulence
characteristic, and the lack of motility of the vaccine strains likely
resulted in suboptimal antigen delivery to sampling sites within
the intestinal mucosa.36 In addition, highly conserved regions of
ﬂagellin that ﬂank serotype speciﬁc regions of the molecule may
not only serve as potent stimuli of innate immunity, but contain
cross-protective epitopes.29 Intriguingly, addition of dmLT as a
mucosal adjuvant signiﬁcantly enhanced the response to multiple
ﬂagellins independent of whether the speciﬁc serotype was
present in the vaccine.
The genomes of the three vaccine strains and parents also
revealed that the etpBAC locus, which encodes the two-partner
secretion system responsible for production and export of the
Fig. 3 ALS IgA responses to non-canonical secreted antigens. a Comparison of ALS IgA responses against IVTT-produced ﬂagellins
representing the serotypes of the ACE527 strains (H5, H16, H45) and the H10407 challenge strain (H11). Shown are responses to three
recombinant protein antigens: b YghJ, c the passenger domain of EatA (EatAp), and d the amino terminal region of EtpA (EtpA_N) secreted by
the ETEC H10407 challenge strain and/or the ACE527 vaccine strains. Columns in each group represent data obtained at day 0, day 7 following
vaccination, or day 7 following challenge with abbreviated labels of “0”, “7”, and “ch” respectively. Data in each vaccination or control group are
represented as corrected for the baseline values obtained at day 0. Each symbol represents the change in normalized ALS IgA signal at
baseline (day 0) to day 7 post immunization or after placebo administration. Values on the y-axis for B-D are expressed as the % difference of
(signal-background)/background. (*<0.05, **<0.01, ***<0.001, **** ≤ 0.0001 by ANOVA comparison of normalized signal data with
corresponding day 0 data without background correction; Kruskal–Wallis test for multiple comparisons). Open bars represent mean values
S. Chakraborty et al.
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EtpA adhesin,18 was present in two of the three parental strains
but missing from the vaccine altogether, likely the result of
engineering the vaccine strains to remove the plasmid-encoded
toxins. EtpA is a high molecular weight glycoprotein secreted by
ETEC that appears to facilitate bacterial adhesion by serving as a
molecular bridge between ﬂagella 37and the enterocyte surface
where it binds to N-acetylgalactosamine (GalNAc) residues38
particularly when they are presented as the terminal glycan on
human A blood group antigen. Interestingly, human challenge
studies with H10407 demonstrate that individuals with A blood
group are signiﬁcantly more likely to experience severe diarrhea
when challenged with this EtpA-producing strain.22 These and
other recent studies12 demonstrate that EtpA is highly immuno-
genic and recognized by the majority of volunteers upon
challenge with wild-type H10407, in distinct contrast to those
immunized with ACE527 ± dmLT. Although EtpA is required for
optimal delivery of both LT and ST enterotoxins, and is protective
against ETEC infection in a murine model, further studies are
needed to assess its role as a potential protective antigen in
humans.
Protective immunity to ETEC is likely complex and may
represent the cumulative response to E. coli core proteins, classical
vaccine antigens, and more recently discovered proteins.
Although the present studies, based on small numbers of human
volunteers, do not permit us to establish clear mechanistic
correlates of protection, they highlight the utility of combined
genomic, proteomic and immunoproteomic platforms in inter-
preting the response to live-attenuated vaccines.
Comparison of the vaccine antigen content and immunologic
responses to those observed with wild-type infection could inform
the design, optimization, and engineering of next-generation ETEC
vaccines to enhance protective efﬁcacy. Moreover, the platforms
used in the present studies could be generalized to interrogation
of live-attenuated vaccines for other important pathogens.
METHODS
Bioinformatics and comparative genomics of ETEC isolates
To select candidate genes for protein expression, we analyzed the
previously sequenced genomes of three parental ETEC isolates WS_1858B,
WS_2773E, and WS3504D, used in the construction of ACE527,13 the
genome of E. coli H1040739 the challenge strain used in these studies, and
the genomes of a diverse group of clinical isolates. Data describing these
strains is presented in supplementary table 1. The genome content of
these isolates was compared using Large-Scale BLAST Score Ratio
Analysis40 and encoded products having a signal for potential secretion
to the surface were identiﬁed using PSORT,41 TMHMM,42 and SignalP.43
The resulting dataset includes 800 antigens identiﬁed in H10407, 157
antigens present in one or more of the three isolates of the ACE527
vaccine lacking in the H10407 genome, and an additional 4168 features
identiﬁed in comparative analysis of 207 clinical ETEC isolates (supple-
mentary data s1).44,45 The selected 4168 gene features were present in
more than 40% of the ETEC isolates and were not present in the genomes
of three common E. coli commensal isolates E. coli HS (GenBank Accession
number NC_009800), E. coli K-12 (GenBank Accession number
NC_007779.1), E. coli ATCC8739 (GenBank Accession number NC_010468)
or E. coli IAI1 (GenBank Accession number NC_011741). Gene identiﬁers,
DNA and predicted peptide sequences, and the isolates used as the
template for isolation are included in supplementary_data_s1. Informati-
cally selected features encompassed known ETEC antigens including the A
and B subunits of heat-labile toxin (LT-A, and LT-B),CFs, the EatA19 serine
protease, the EtpA adhesin,37 and the metalloprotease YghJ46 in addition
to conserved and serotype speciﬁc regions of ﬂagellin molecules
represented in the challenge and vaccine strains.
Rapid Annotation using Subsystem Technology (RASTtk v 1.3.0, http://
rast.nmpdr.org) 47was used to query completed ACE527 genomes for
speciﬁc virulence factors. Multiplex PCR was used to verify the toxin
proﬁles of parent and ACE527 vaccine strains using primers for estH, estP,
and eltB encoding the STh, STp, and the B subunit of LT, respectively.48 PCR
was also used to verify the presence or absence of the eatA and etpA
genes.49 (supplementary table 2). SerotypeFinder v 2.0 (https://cge.cbs.dtu.
dk/services/SerotypeFinder/) was used to assign H serotypes from whole
genome sequence data.50
Microarray construction
Genes encoding candidate ETEC surface-expressed antigens were ampli-
ﬁed by PCR, cloned into pXI T7,12,51 and expressed in a cell-free in vitro
transcription—translation (IVTT) system as previously described.12 Each
IVTT protein included 5′ polyhistidine (HIS) and 3′ hemagglutinin (HA)
epitopes. After robotic microarray printing onto nitrocellulose-coated glass
slides, random slides were validated by probing with anti-His (mouse
monoclonal clone HIS-1, Sigma-Aldrich, H1029-100UL) and anti-HA (rat
monoclonal to HA peptide YPYDVPDYA, clone 3F10, Sigma Aldrich,
11867423001) followed by ﬂuorescent secondary antibodies.
Recombinant antigens including the EtpA adhesin,52 the passenger
domain of EatA,19 YghJ,46 antigen 43,53 EaeH,54 LT-A and LT-B, and ﬂagellin
(FliC)29 subunits were produced at Washington University in Saint Louis as
Table 2. Most differentially reactive IVTT antigens ALS IgA, responses day 0 to day 7 following ACE527 or ACE527+ dmLT
ACE527 ACE527+ dmLT
Antigen Δa Frequencyb p Antigen Δa Frequencyb p
EatA AA 533–1045 2.62 0.75 1.6 × 10
–3 EatA AA 533–1045 3.95 0.85 5.1 × 10
–5
EatA AA 1–1364 0.98 0.33 3.8 × 10
–2 EatA AA 1–1364 1.83 0.70 6.1 × 10
–4
WS1858B FliC (H45) 0.90 0.25 6.8 × 10–2 Antigen 43 1.33 0.39 3.5 × 10–2
WS3504D_05115c 0.65 0.17 1.8 × 10–1 WS2773E FliC (H5) 1.18 0.69 2.8 × 10–3
CS3 pilin subunit A 0.65 0.17 1.7 × 10–1 H10407 FliC (H11) 1.16 0.80 1.9 ×10–3
Centroid_475810c 0.56 0.25 9.8 × 10–2 CfaB CFA/I pilin 1.04 0.30 6.5 × 10–2
WS2773E FliC (H5) 0.52 0.33 2 × 10–1 CS3 pilin 0.94 0.23 6.25 × 10–2
H10407 FliC (H11) 0.45 0.17 6.4 × 10–2 WS1858B FliC (H45) 0.90 0.46 6.6 × 10–3
Centroid_845698d 0.38 0.17 1.6 × 10–1 LT-A 0.81 0.39 1.7 × 10–2
Prophage integrase c577664 0.36 0.25 7.8 × 10–2 Transcriptional activator CadC 0.76 0.54 5.8 × 10–3
Transcriptional activator CadC 0.33 0.17 1.4 × 10–1 Aldehyde dehydrogenase PuuC 0.70 0.23 9.1 × 10–2
aΔmean refers to difference in mean values at day 0 prior to challenge and day 7 post challenge
bFrequency refers to the proportion of subjects with at least a 50% increase in normalized signal intensity between day 0 and day 7 after the ﬁrst vaccination
challenge
cHypothetical protein
dPutative quorum sensing protein
S. Chakraborty et al.
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previously described. Puriﬁed CFs, and CS antigens were produced at the
Naval Medical Research Center, Silver Spring Maryland.
Microarray antigen content
The microarrays used in this study were comprised of IVTT expressed
proteins selected above and puriﬁed proteins representing known ETEC
antigens (n= 38) (Supplementary dataset s1). Also included on the array
are IVTT control spots (n= 28), positive control spots for IgG secondary
antibody (n= 16), positive controls for human IgG (n= 16), positive control
spots for IgA secondary antibody (n= 16), and positive controls for human
IgA (n= 16).
Vaccination with ACE527 and controlled human infection studies
Samples analyzed in the present study were derived from Phase 1/2b trial
of ACE527 conducted in healthy human volunteers at the Centre for
Immunization Research at Johns Hopkins University School of Public
Health (clinical trial number NCT01739231).27 In this earlier trial, subjects
were randomly assigned to three groups: the placebo group or groups that
received three doses of ACE527 (~1010 cfu/dose) given orally with or
without the dmLT adjuvant (25 μg per dose). At 6–7 months following the
primary immunization, placebo and vaccine ± dmLT immunization subjects
were rescreened for eligibility. Those enrolled were challenged with ~2 x
107 colony forming units (cfu) of the H10407 ETEC challenge strain after an
overnight fast, and assessed in an inpatient setting for development of
ETEC-associated diarrhea and other signs and symptoms of enteric illness.
The challenge phase of this study included 13 volunteers who received
three oral doses of ACE527, 13 volunteers who received three oral doses
ACE527 adjuvanted with 25 µg of dmLT, and 10 placebo recipients
(supplementary dataset s1).
ETEC strain validation
Strains used in these studies are summarized in supplementary table 1. The
H10407 clinical challenge strain used in these studies was derived from
cGMP Batch Production Record (BPR)-285-01, Lot 1514, manufactured on
15 October 2008 at the Walter Reed Army Institute of Research (WRAIR)
Pilot Bio-production Facility, Silver Spring, Maryland. cGMP aliquots of
vaccine strains ACAM2022 (BPR-966-00, lot 1621, manufactured 08 March,
2010), ACAM 2025 (BPR-977-00, lot 1633, manufactured 03 May, 2010), and
ACAM2027 (BPR-969-00, lot 1625, manufactured 22 March, 2010) were
obtained as lyophilized frozen stocks from WRAIR. Parent ETEC isolates WS-
2773E, WS-3504D, and WS-1858B used to engineer the vaccine strains
were forwarded from the University of Maryland. The toxin proﬁle of each
isolate was conﬁrmed by multiplex PCR using primers for eltB, estH, and
estP; and etpA and eatA genes fragments were ampliﬁed as described
previously (supplementary table 2). To verify production of secreted
proteins, immunoblotting for EtpA, EatA, and YghJ was performed as
previously described.55 All immunoblots derive from the same experiment
and were processed in parallel. Immunoblotting used afﬁnity puriﬁed cross
absorbed rabbit polyclonal antibodies against each of the respective
recombinant proteins. The secondary antibody used for detection was
goat anti-rabbit antibody conjugated to IRDye 680RD. (Catalogue number
925-68071).
Production of subcellular fractions and proteome analysis
In characterizing the proteomes of the ACE527 vaccine strains and parents,
subcellular fractions including outer membrane proteins (OMPs), outer
membrane vesicles (OMV), and concentrated culture supernatants were
prepared for tryptic digestion and peptide analysis using high resolution
tandem mass spectrometry interfaced to nano-liquid chromatography (LC-
MS/MS) as recently described for H10407.12 LC-MS data were used to
search (MASCOT, version 2.5.1, Matrix Science, London, UK) conceptionally
translated genomes of parent and vaccine strains (see bioproject
PRJEB2286). The complete set of mass spectrometry data is included in
supplementary dataset s2.
Antibody lymphocyte supernatants
ALS were prepared from whole blood by isolation of PBMC, followed by
in vitro culture of the PBMCs as previously described.24 The resulting
supernatants were then stored at −80 °C for future use in these studies.
Statistical analysis
Array comparisons were reported as the proportion of subjects with at
least a 50% increase in normalized signal intensity between day 0 and
day 7. p values reported in tables represent t-test comparisons of average
normalized signals obtained for the two represented groups. In presenta-
tion of graphs where multiple comparisons are made, ANOVA was used to
Table 3. Differentially reactive IVTT antigens following ETEC H10407 challenge of naive subjects
Antigen Δ meana Frequencyb p
FliC H11 6.06 0.90 5.8 × 10–5
Antigen 43 3.77 0.70 2.4 × 10–3
FliC H11 AA 174–399 (H11 serotype speciﬁc) 2.88 0.90 1.4 × 10
–4
EatA passenger domain AA 533–1045 2.68 0.70 1.1 × 10
–2
YghJ metalloprotease AA 695–1493 2.50 0.80 1.8 × 10
–3
FlgE ﬂagellar hook 1.51 0.60 2.8 × 10–2
OmpW 1.45 0.70 5.4 × 10–3
YghJ metalloprotease AA 1–800 1.19 0.70 4.3 × 10
–3
AIDA-I family autotransproter YfaL 1.09 0.60 1.4 × 10–2
EatA serine protease AA 1–1364 0.99 0.40 3.9 × 10
–2
aΔmean refers to difference in mean values at day 0 prior to challenge and day 7 post challenge
bFrequency refers to the proportion of subjects with at least a 50% increase in normalized signal intensity between day 0 and day 7 post challenge
Table 4. Differentially reactive puriﬁed protein antigens following
ETEC H10407 challenge of naive subjects
Antigen Δ meana Frequencyb p
YghJ 5.40 0.90 1.1 × 10–4
CS14 4.85 0.90 1.8 × 10–5
EtpA amino-terminal domain 4.08 0.90 1.6 × 10–3
CS2 2.74 0.90 4.7 × 10–3
CS3 2.37 0.90 2.5 × 10–3
CS1 2.29 0.80 5.6 × 10–3
PCF071 2.29 0.80 1.9 × 10–3
EatAp 2.64 0.70 5.7 × 10–3
CS17 2.37 0.70 1.2 × 10–2
EtpA full length 1.34 0.70 8.1 × 10–3
aΔmean refers to difference in mean values at day 0 prior to challenge and
day 7 post challenge
bFrequency refers to the proportion of subjects with at least a 50% increase
in normalized signal intensity between day 0 and day 7 post challenge
S. Chakraborty et al.
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compare normalized signal data with a Kruskal–Wallis test for multiple
comparisons.
Human studies
Use of the archived biospecimens, and data in the present study was
performed with the approval of the Institution Review Boards of Johns
Hopkins University School of Medicine and Washington University School
of Medicine.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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Proteomics data have been uploaded to the ProteomeXchange56,57 database
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